Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

Poor bowel preparation also led to repeat colonoscopies for 18.9% of current GLP-1RA users, compared to 11.1% of controls ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration ...

The GLP-1 medications liraglutide and semaglutide ... they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views ...

HM17321 addresses a key limitation in current GLP-1-based therapies, which often lead to muscle loss as a side effect of significant weight reduction. “HM17321 is the novel concept of obesity drug ...

Earlier this month, the FDA put out a statement saying that it, too, was concerned about patients and healthcare professionals turning to unapproved versions of GLP-1 drugs as an option for weight ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

Brokerages have shared mixed sentiment on Divi’s Laboratories following its September-quarter performance, highlighting the ...